Current parathyroid hormone immunoassays do not adequately meet the needs of patients with chronic kidney disease

Annals of Clinical Biochemistry

Volumn 49, Issue 1, 2012, Pages 63-67

  Almond, Alison ^a   Ellis, Andrew R ^a,b   Walker, Simon W ^c  

^a DUMFRIES AND GALLOWAY ROYAL INFIRMARY   (United Kingdom)

^b UK National External Quality Assessment Service (UK NEQAS)   (United Kingdom)

^c ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PARATHYROID HORMONE;

ARTICLE; CHRONIC KIDNEY DISEASE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HUMAN TISSUE; IMMUNOASSAY; INTERMETHOD COMPARISON; PARATHYROID HORMONE BLOOD LEVEL; PILOT STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL;

HUMANS; IMMUNOASSAY; KIDNEY; PARATHYROID HORMONE; PRACTICE GUIDELINES AS TOPIC; REFERENCE STANDARDS; REFERENCE VALUES; REGRESSION ANALYSIS; RENAL INSUFFICIENCY, CHRONIC; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84855913912     PISSN: 00045632     EISSN: 17581001     Source Type: Journal    
DOI: 10.1258/acb.2011.011094     Document Type: Article

References (16)

1. Quarles LD, Lobaugh B, Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 1992;75:145-50
2. National Kidney F. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:S1-201
3. Kidney Disease: Improving Global Outcomes C-MWG. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009;113:S1-130
4. Goldsmith DJ, Covic A, Fouque D, et al. Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement. Nephrol Dial Transplant 2010;25:3823-31
5. Wang M, Hercz G, Sherrard DJ, et al. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis 1995;26:836-44
6. Torres A, Lorenzo V, Hernandez D, et al. Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH. Kidney Int 1995;47:1434-42
7. Steddon S, Sharples E. Renal Association Clinical Practice Guideline in mineral and bone disorders in CKD. Nephron Clin Pract 2011;118:(Suppl 1):c145-52
8. National Institute for Health and Clinical Excellence. NICE technology appraisal guidance 117. Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy. See http://guidance.nice.org.uk/TA117 (last checked 31 August 2011)
9. Souberbielle JC, Boutten A, Carlier MC, et al. Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int 2006;70:345-50
10. Souberbielle JC, Cormier C, Kindermans C, et al. Vitamin D status and redefining serum parathyroid hormone reference range in the elderly. J Clin Endocrinol Metab 2001;86:3086-90
11. Monge M, Jean G, Bacri JL, et al. Higher parathyroid hormone (PTH) concentrations with the Architect PTH assay than with the Elecsys assay in hemodialysis patients, and a simple way to standardize these two methods. Clin Chem Lab Med 2009;47:362-6
12. Sturgeon CM, Ellis AR, Al-Sadie R. UK NEQAS for Peptide Hormones: Annual Review for 2009. Edinburgh: UK NEQAS, 2010:26-30
13. Passing H, BablokW. Comparison of several regression procedures for method comparison studies and determination of sample sizes.Application of linear regression procedures for method comparison studies in Clinical Chemistry, Part II. J Clin Chem Clin Biochem1984;22:431-45
14. Cantor T, Yang Z, Caraiani N, et al. Lack of comparability of intact parathyroid hormone measurements among commercial assays for end-stage renal disease patients: implication for treatment decisions. Clin Chem 2006;52:1771-6
15. Sprague SM. Renal bone disease. Curr Opin Endocrinol Diabetes Obes 2010;17:535-9
16. Sturgeon C, Fraser WD. Lack of comparability of PTH measurements - the urgent clinical need for improvement. Clin Chem Lab Med 2011;49(Suppl.):575